Literature DB >> 14678202

The classical and alternative pathways of complement activation play distinct roles in spontaneous C3 fragment deposition and membrane attack complex (MAC) formation on human B lymphocytes.

Robert Graham Quinton Leslie1, Claus Henrik Nielsen.   

Abstract

The contributions of the classical (CP) and alternative (AP) pathways of complement activation to the spontaneous deposition of C3 fragments and the formation of membrane attack complexes (MAC) on human B lymphocytes, were assessed by incubating peripheral blood mononuclear cells with autologous serum in the absence and presence of selective inhibitors of the AP and CP, respectively. While the total amount of C3 fragments deposited was relatively unaffected by blocking either pathway individually, deposition was virtually abrogated by their combined blockade. A marked difference was observed, however, in the nature of the fragments deposited as a result of CP and AP activation: C3b fragments deposited via the CP were extensively ( approximately 90%) converted to the terminal degradation product, C3dg, whereas about 50% of those deposited by the AP persisted as C3b/iC3b fragments. The extent of MAC formation was also found to be highly pathway dependent, with the AP being about 15-fold more efficient at initiating this process than the CP. A model accounting for the effectiveness of the AP in both preserving C3 fragment integrity and initiating MAC is presented.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14678202      PMCID: PMC1782389          DOI: 10.1111/j.1365-2567.2004.01780.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  18 in total

1.  The influence of complement receptor type 1 (CD35) and decay-accelerating factor (CD55) on complement receptor type 2- (CD21) mediated alternative pathway activation by B cells.

Authors:  R G Leslie
Journal:  Immunology       Date:  1999-07       Impact factor: 7.397

2.  The role of complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) in promoting C3 fragment deposition and membrane attack complex formation on normal peripheral human B cells.

Authors:  Claus Henrik Nielsen; Morten Løbner Pedersen; Hanne Vibeke Marquart; Wolfgang Maria Prodinger; Robert Graham Quinton Leslie
Journal:  Eur J Immunol       Date:  2002-05       Impact factor: 5.532

3.  CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytes.

Authors:  C H Nielsen; H V Marquart; W M Prodinger; R G Leslie
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

4.  Complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) cooperate in the binding of hydrolyzed complement factor 3 (C3i) to human B lymphocytes.

Authors:  Robert Graham Quinton Leslie; Wolfgang Maria Prodinger; Claus Henrik Nielsen
Journal:  Eur J Immunol       Date:  2003-12       Impact factor: 5.532

5.  Functionally active C1 on the surface of human peripheral lymphocytes: its role in the complement-mediated inhibition of the Fc receptor of B lymphocytes.

Authors:  G Füst; A Erdei; G Sármay; G A Medgyesi; J Gergely
Journal:  Clin Immunol Immunopathol       Date:  1976-05

6.  CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.

Authors:  C Mold; G R Nemerow; B M Bradt; N R Cooper
Journal:  J Immunol       Date:  1988-03-15       Impact factor: 5.422

7.  Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity.

Authors:  G D Ross; J D Lambris; J A Cain; S L Newman
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

8.  Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma.

Authors:  T E Mollnes; T Lea; M Harboe; J Tschopp
Journal:  Scand J Immunol       Date:  1985-08       Impact factor: 3.487

9.  Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype.

Authors:  Claudia Kemper; Andrew C Chan; Jonathan M Green; Kelly A Brett; Kenneth M Murphy; John P Atkinson
Journal:  Nature       Date:  2003-01-23       Impact factor: 49.962

10.  Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis.

Authors:  L B Klickstein; T J Bartow; V Miletic; L D Rabson; J A Smith; D T Fearon
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

View more
  5 in total

Review 1.  Complement-induced impairment of the innate immune system during sepsis.

Authors:  Eric A Albrecht; Peter A Ward
Journal:  Curr Allergy Asthma Rep       Date:  2004-09       Impact factor: 4.806

2.  Complement-induced Impairment of the Innate Immune System During Sepsis.

Authors:  Eric A Albrecht; Peter A Ward
Journal:  Curr Infect Dis Rep       Date:  2005-09       Impact factor: 3.725

3.  Complement-dependent neutrophil recruitment is critical for the development of elastase-induced abdominal aortic aneurysm.

Authors:  Monica B Pagano; Hui-fang Zhou; Terri L Ennis; Xiaobo Wu; John D Lambris; John P Atkinson; Robert W Thompson; Dennis E Hourcade; Christine T N Pham
Journal:  Circulation       Date:  2009-03-23       Impact factor: 29.690

4.  C1q ablation exacerbates amyloid deposition: A study in a transgenic mouse model of ATTRV30M amyloid neuropathy.

Authors:  Elena Panayiotou; Eleni Fella; Revekka Papacharalambous; Stavros Malas; Maria Joao Saraiva; Theodoros Kyriakides
Journal:  PLoS One       Date:  2017-04-13       Impact factor: 3.240

5.  Circulating mitochondrial DNA is an early indicator of severe illness and mortality from COVID-19.

Authors:  Davide Scozzi; Marlene Cano; Lina Ma; Dequan Zhou; Ji Hong Zhu; Jane A O'Halloran; Charles Goss; Adriana M Rauseo; Zhiyi Liu; Sanjaya K Sahu; Valentina Peritore; Monica Rocco; Alberto Ricci; Rachele Amodeo; Laura Aimati; Mohsen Ibrahim; Ramsey Hachem; Daniel Kreisel; Philip A Mudd; Hrishikesh S Kulkarni; Andrew E Gelman
Journal:  JCI Insight       Date:  2021-02-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.